News
Abu Abraham, M.D.’s appointment as Chief Medical Officer
We are pleased to announce that Abu Abraham, M.D. has joined as the group’s Chief Medical Officer. Dr. Abu Abraham has over 20
New drug CBT-009 approved to conduct Phase I/II clinical trial in Australia
We are pleased to announce that Australia regulatory agency has approved our application to conduct Phase I/II trial in Australia to evaluate safety, tolerability and
Dr. Jinsong Ni awarded Shishan Technology Innovation and Entrepreneurship “Leading Talent” title
Jinsong Ni, Ph.D, founder and CEO of Cloudbreak Pharma, has been recently awarded the title of Shishan Technology Innovation and Entrepreneurship “Leading Talent” in Suzhou
Cloudbreak Pharma joins Ophthalmology Tech Summit 2022
We are thrilled to participate in and be an Event Sponsor of the Ophthalmology Tech Summit 2022, which will be held on June 16-17 at
Ms. Rebecca Chan, a former senior executive of the Listing Division of the Hong Kong Stock Exchange and ex-partners of three out of four big four international firms, joins Cloudbreak Pharma as the Chief Financial Officer
Cloudbreak Pharma is pleased to announce that Ms. Rebecca Chan has joined as the group’s Chief Financial Officer. Rebecca’s contributions will be instrumental to Cloudbreak
Cloudbreak completed Phase II Clinical Trial for CBT-006 in the U.S. for the treatment of Meibomian Gland Dysfunction associated Dry Eye Disease
Cloudbreak Pharma has announced that the last patient has exited the study of the Phase II clinical trial in the U.S on May 17, 2022